Pulmonx Corp. (LUNG), a commercial-stage medical technology company, is scheduled to report financial results for the second quarter ended June 30, 2024, after the close of trading on July 31.
The company is a provider of minimally invasive treatments for chronic obstructive pulmonary disease, and its marketed products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com